Compass Pathways PLC Sponsored ADR $CMPS Shares Acquired by Royal Bank of Canada

Royal Bank of Canada grew its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 35.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 244,526 shares of the company’s stock after buying an additional 63,358 shares during the period. Royal Bank of Canada’s holdings in Compass Pathways were worth $1,352,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Toronto Dominion Bank increased its position in shares of Compass Pathways by 152.9% in the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the period. Nantahala Capital Management LLC lifted its position in Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares during the period. Ameriprise Financial Inc. acquired a new stake in Compass Pathways during the 3rd quarter worth about $6,926,000. Orbimed Advisors LLC purchased a new stake in Compass Pathways during the 1st quarter valued at about $6,363,000. Finally, Siren L.L.C. acquired a new position in shares of Compass Pathways in the fourth quarter valued at about $6,900,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CMPS. HC Wainwright dropped their target price on Compass Pathways from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Friday, July 17th. UBS Group set a $18.00 price objective on shares of Compass Pathways in a research note on Thursday, May 7th. Wells Fargo & Company assumed coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an “equal weight” rating and a $13.00 target price for the company. Finally, Stifel Nicolaus increased their price target on Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.36.

Compass Pathways Trading Up 0.8%

Compass Pathways stock opened at $14.01 on Thursday. The firm has a market cap of $1.94 billion, a PE ratio of -3.03 and a beta of 2.50. Compass Pathways PLC Sponsored ADR has a 12 month low of $3.97 and a 12 month high of $15.40. The stock’s 50 day simple moving average is $12.78 and its two-hundred day simple moving average is $9.73. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current year.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.